Phase 2 N=16 A Study to Evaluate SAGE-217 in Participants With Essential Tremor
Essential Tremor
Primary: Part A: Change From Baseline in Accelerometer-based Kinesia Kinetic Tremor Combined Score at Day 7 — 4.36; -0.69 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols
Advanced Solid Tumors
Primary: Extent of Exposure to ARQ 197 in Participants Benefiting From Prior ARQ 197 Therapy — 125 Days
Phase 1 N=32 A Study in Healthy Men and Women to Test Which Effects Donepezil and BI 425809 Have on Each Other
Healthy
Primary: Area Under the Concentration-time Curve of BI 425809 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 11815.37; 10944.06 nanomoles * hours per…
Phase 4 N=36 Use of Forteo (Teriparatide) in Posterolateral Lumbar Spine Fusion
Lumbar Spondylosis · Lumbar Spondylolisthesis · Adult Degenerative Lumbar Scoliosis
Primary: Quality of Spine Fusion, Measured by the Number of Participants With Complete Spine Fusion at 1 Year — 11; 6 Participants
N/A N=26 MINIject in Patients With Open Angle Glaucoma Uncontrolled by Topical Hypotensive Medications
Open Angle Glaucoma
Primary: Change in Medicated Diurnal Intra-ocular Pressure (IOP) at 6 Months Post-implantation — -8.95 mmHg
Phase 2 N=15 Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency · Emphysema · Chronic Obstructive Pulmonary Disease
Primary: Pulmonary Microvascular Blood Flow, Mean — 36.9; 35.1 mL blood/minute per 100mL lung — p=0.692
Phase 4 N=104 Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc
Healthy Volunteers · Diabetes Mellitus, Type 2 · Overweight
Primary: Intensity of Injection Site Pain — 5.6; 11.5 Score on a scale — p=<0.0001
Phase 1 N=69 First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors
Tumors
Primary: Dose-Escalation Phase: Maximum Tolerated Dose (MTD) of Mirvetuximab Soravtansine — 6.0; 2.0 mg/kg
Phase 1 N=25 A Study of Olaratumab in Japanese Participants With Advanced Cancer
Neoplasm
Primary: Part A: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 1; 4; 1…
Phase 2 N=10 A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia
Primary: Number of Participants With Reduction of 17-hydroxyprogesterone to </= 2 Times the Upper Limit of Normal at Any Time Following 2 Weeks of Dosing With ATR-101 — 2…
Phase 4 N=101 Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)
Pain, Postoperative · Crohn Disease · Inflammatory Bowel Diseases
Primary: Cumulative 48-hour Post Surgical Opiate Use (Oral Morphine Equivalent) — 47; 69 Oral morphine equivalents
Phase 2 N=91 A Study of UCB and MSCs in Children With CP: ACCeNT-CP
Cerebral Palsy
Primary: Change in Gross Motor Function Measure (GMFM-66) in Excess of Expected Change — 5.83; 4.27; 3.15 score on a scale
N/A N=901 The OPTI Study in Spain Looks at the History Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Inhaled Steroids.
Pulmonary Disease, Chronic Obstructive
Primary: Percentage of Patients Currently on Inhaled CorticoSteroids (ICS) Who Did Not Have Moderate or Severe Exacerbation in the Year Prior to the Study Visit — 62.5 Percentage…
N/A N=2,169 MultiPoint Pacing™ Post Market Study
Heart Failure
Primary: Number of CRT Responders as Measured by the Clinical Composite Score (CCS) — 350 Participants
N/A N=101 Heart Function in Patients Assessed for Sleep Apnoea
Heart Failure With Preserved Ejection Fraction · Sleep Disordered Breathing · Heart Failure With Normal Ejection Fraction
Primary: Number of Participants With Unrecognised Heart Failure With Preserved Ejection Fraction (HFpEF) in Cohort With Clinically Suspected Sleep Disordered Breathing (SDB) — 7…